Sarepta Therapeutics | SRPT - Current Assets



Sarepta Therapeutics reported $2.66B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Acadia Pharmaceuticals USD 960.55M 89.61M Jun/2025
Agios Pharmaceuticals USD 1.02B 50.85M Jun/2025
Alnylam Pharmaceuticals USD 3.64B 375.44M Jun/2025
Amgen USD 26.73B 195M Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Daiichi Sankyo JPY 1.85T 62.54B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
Incyte USD 3.64B 411.91M Jun/2025
Insmed USD 2.08B 678.89M Jun/2025
Ionis Pharmaceuticals USD 2.58B 158.22M Jun/2025
Moderna USD 6.17B 595M Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
PTC Therapeutics USD 2.27B 43.53M Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024
Sanofi 37.02B 7B Jun/2025
Sarepta Therapeutics USD 2.66B 224.45M Jun/2025
Tectonic Therapeutic USD 290.85M 143.99M Jun/2025
Ultragenyx Pharmaceutical USD 719.79M 20.63M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025